Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17395754 | 0.79 | NOS1 (0.35) | CHRM2CHRM1NOS1 | |
| SCHEMBL17402473 | 0.79 | NOS1 (0.35) | CHRM2CHRM1NOS1 | |
| SCHEMBL18914928 | 0.76 | — | — | |
| SCHEMBL27017038 | 0.76 | — | — | |
| SCHEMBL14257103 | 0.76 | — | — | |
| SCHEMBL17154404 | 0.72 | — | — | |
| SCHEMBL16870301 | 0.70 | — | — | |
| SCHEMBL18474058 | 0.69 | — | — | |
| SCHEMBL10818681 | 0.66 | — | — | |
| SCHEMBL18474182 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084783-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated with an accumulation of misfolded proteins | INFLECTIS BIOSCIENCE (FR) | 2021-08-10 | — | — | US | disclosed |
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | INFLECTIS BIOSCIENCE (FR) | 2020-06-09 | — | — | US | disclosed |
| US-20200102269-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH AN ACCUMULATION OF MISFOLDED PROTEINS | INFLECTIS BIOSCIENCE (FR) | 2020-04-02 | — | — | US | disclosed |
| US-10544093-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins | INFLECTIS BIOSCIENCE (FR) | 2020-01-28 | — | — | US | disclosed |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | INFLECTIS BIOSCIENCE (FR) | 2018-08-09 | — | — | US | disclosed |
| US-20170152220-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS | INFLECTIS BIOSCIENCE (FR) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152220-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS | HSPA5, PRNP, MAPT | CHRM2 4256/4885CHRM1 4459/4885BTN3A1 852/4885 |
| US-20200102269-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH AN ACCUMULATION OF MISFOLDED PROTEINS | HSPA5, PRNP, TBCA | CHRM2 4217/4885CHRM1 4486/4885BTN3A1 1030/4885 |
| US-10544093-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins | HSPA5, PRNP, MAPT | CHRM2 4256/4885CHRM1 4459/4885BTN3A1 852/4885 |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | MGMT, GLI1, CA9 | CHRM2 4425/4885CHRM1 4769/4885BTN3A1 2747/4885 |
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | MGMT, GLI1, CA9 | CHRM2 4425/4885CHRM1 4769/4885BTN3A1 2747/4885 |
| US-11084783-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated with an accumulation of misfolded proteins | HSPA5, PRNP, TBCA | CHRM2 4217/4885CHRM1 4486/4885BTN3A1 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.